Abstract
The joint effects of APOE genotype and DNA methylation on Alzheimer disease (AD) risk is relatively unknown. We conducted genome-wide methylation analyses using 2,021 samples in blood (91 AD cases, 329 mild cognitive impairment, 1,391 controls) and 697 samples in brain (417 AD cases, 280 controls). We identified differentially methylated levels in AD compared to controls in an APOE genotype-specific manner at 25 cytosine-phosphate-guanine (CpG) sites in brain and 36 CpG sites in blood. Additionally, we identified seven CpG sites in the APOE region containing TOMM40, APOE, and APOC1 genes with P<5×10−8 between APOE ε4 carriers and non-carriers in brain or blood. In brain, the most significant CpG site hypomethylated in ε4 carriers compared to non-carriers) was from the TOMM40 in the total sample, while most of the evidence was derived from AD cases. However, the CpG site was not significantly modulating expression of these three genes in brain. Three CpG sites from the APOE were hypermethylated in APOE ε4 carriers in brain or blood compared in ε4 non-carriers and nominally significant with APOE expression in brain. Three CpG sites from the APOC1 were hypermethylated in blood, which one of the 3 CpG sites significantly lowered APOC1 expression in blood using all subjects or ε4 non-carriers. Co-methylation network analysis in blood and brain detected eight methylation networks associated with AD and APOE ε4 status. Five of the eight networks included genes containing network CpGs that were significantly enriched for estradiol perturbation, where four of the five networks were enriched for the estrogen response pathway. Our findings provide further evidence of the role of APOE genotype on methylation levels associated with AD, especially linked to estrogen response pathway.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by the National Institute on Aging (NIA) grants, RF1AG057519, R01AG069453, U01AG068057, U19AG068753, P30AG072978, U01AG032984, R56AG069130, R01AG048927, U01AG062602, U01AG058654, RF1AG057768, and RF1AG054156. ROSMAP is supported by P30AG10161, P30AG72975, R01AG15819, R01AG17917, R01AG36042, U01AG46152, and U01AG61356. FHS is supported by National Heart, Lung and Blood Institute (75N92019D00031 and HHSN2682015000011).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol, design, and performance of the current study were approved by the Boston University Institutional Review Board.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
FHS data are available on the dbGaP (Study Accession ID: phs000056.v5.p3). ROSMAP resources can be requested at from the CommonMind Consortium portal (http://www.synapse.org). Data used in preparation of this article were obtained from the Alzheimer Disease Neuroimaging Initiative (ADNI) database (http://adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at: http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf.
Abbreviations
- AD
- Alzheimer’s Disease
- ADAS13
- Alzheimer’s Disease Assessment Scale – 13 item
- ADNI
- Alzheimer’s Disease Neuroimaging Initiative
- BNT30
- Boston Naming Test
- CDRSB
- Clinical Dementia Rating Scale Sum of Boxes
- CERAD
- Consortium to Establish a Registry for Alzheimer Disease
- CpG
- cytosine-phosphate-guanine
- FAS_animal
- animal portion of the Verbal Fluency Test
- FHS
- Framingham Heart Study
- GRM
- genetic relatedness matrix
- GWAS
- genome-wide association study
- LDELTOTAL
- logical memory - delayed recall
- LMd
- Logical Memories – Delayed Recall
- LMi
- Logical Memories – Immediate Recall
- MCI
- mild cognitive impairment
- MRI
- magnetic resonance imaging
- PASr
- Paired Associate Learning – Recognition
- PMI
- post mortem interval
- RAVLT
- Rey Auditory Verbal Learning Test
- RIN
- RNA integrity number
- ROSMAP
- Religious Orders Study and Rush Memory and Aging Project
- RNA-seq
- RNA sequencing
- SIM
- Similarities Test
- trailsA
- Trail A
- VRd
- Visual Reproductions – Delayed Recall
- WGCNA
- weighted gene correlation network analysis
